Announcements Trials
Browse Landscape

Status

No longer available 2Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 473Observational 11Expanded_access 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Plasma cell 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Primary Myelofibrosis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Amyloidosis 1

Interventions

nilotinib 5venetoclax 3midostaurin 3ponatinib 2navitoclax 2gilteritinib 2fludarabine phosphate 2asparaginase erwinia chrysanthemi recombinant 2tisagenlecleucel 1revumenib 1pirtobrutinib 1magrolimab 1ivosidenib 1immunotoxin HA22 1idelalisib 1ibrutinib 1glucarpidase 1fludarabine 1eryaspase 1enasidenib 1cc-486 1brexucabtagene autoleucel 1asciminib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × venetoclax × Other hematologic neoplasm × Clear all
NCT03123029 2026-01-30

Expanded Access to Venetoclax

AbbVie

Available
LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05215405 2025-02-03

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

University of Texas Southwestern Medical Center

No longer available
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03592576 2024-05-06

Expanded Access to Navitoclax

AbbVie

No longer available
LymphoidMyeloidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡